Abstract Library

#4251 Upfront Oxaliplatin–Fluoropyrimidine chemotherapy and Somatostatin Analogues (SSA) in advanced well-differentiated G2/G3 gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs)

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are frequently diagnosed at advanced stage. For well-differentiated somatostatin receptor-positive (SSTR +) NETs, somatostatin analogues (SSAs) are the preferred first-line therapy. However, in patients (pts) with G2/G3 and a high tumor burden, SSA alone might not be enough.

Conference:

Presenting Author:

Authors: Maratta M, Sparagna I, d'Agostino F, Occhipinti D, Raia S,

Keywords: gastroenteropancreatic NET, neuroendocrine tumor, chemotherapy, conversion surgery, neoadjuvant treatment,

#3516 177Lutetium-Peptide Receptor Radionuclide Therapy (PRRT) safety assessment in patients with refractory Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP NETs)

Introduction: 177Lu-PRRT became an established therapeutic modality in inoperable or metastatic NETs, demonstrating substantial survival benefits and reassuring safety profile. Dosimetry of Organs-At-Risk [OAR, kidneys, bone marrow (BM) and spleen] and malignant lesions ensures to further optimize its safety and efficacy.

Conference:

Presenting Author: van Bogaert C

Authors: van Bogaert C, Mileva M, Marin G, Levillain H, Artigas-Guix C,

Keywords: PRRT, Safety, Dosimetry, Prospective trial,

#3433 Role of [18 F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors

Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasia (NET) is a heterogeneous disease. While 68-Ga PET is considered the gold standard in GEP-NETs, the role of [18F]FDG PET/CT is not well established, particularly in well-differentiated G1 NETs.

Conference:

Presenting Author: Magi L

Authors: Magi L, Prosperi D, Lamberti G, Marasco M, Ambrosini V,

Keywords: Neuroendocrine tumor, disease aggressiveness, prognosis, management, PET,

#3402 Serial liquid biopsies - the NETest - in gastroenteropancreatic NET surveillance

Introduction: Current general biomarkers are insufficient to predict the disease course in individual patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).

Conference:

Presenting Author:

Authors: van Treijen M, Korse C, Verbeek W, Tesselaar M, Valk G,

Keywords: GEP-NET, disease status, prediction, treatment response, surveillance,

#3034 Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is ≥ 10%?

Introduction: The antiproliferative effect of first-line long acting somatostatin analogs (SSA) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) was shown in the PROMID and the CLARINET trials. Efficacy data in pancreatic NETs (PanNETs) with Ki-67 ≥ 10% are limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Merola E

Authors: Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pelle E,

Keywords: Pancreatic NET, Somatostatin Analogs, Grade 2 and 3, Safety, Efficacy,